New medication for acute schizophrenia symptoms
Part of Mental health clinical trials.
This study tests a new medication (LY03020) for people with schizophrenia who are currently having a flare-up of symptoms severe enough to require hospital care. The goal is to see if the drug safely reduces psychotic symptoms like hallucinations and delusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a diagnosis of schizophrenia with current symptoms severe enough to need hospital care (within the last 2 months)
- Score at least 80 on a schizophrenia symptom rating scale (PANSS), including moderate or worse hallucinations, delusions, or disorganized thinking
- Not have tried clozapine (a strong antipsychotic) in the past, or have been diagnosed with treatment-resistant schizophrenia
- Not have certain heart conditions, such as long QT syndrome, recent heart attack, or unstable angina
- Not have had electroconvulsive therapy (ECT) in the last 3 months
- Not have had suicidal thoughts or attempts in the past 6 months to 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety of a new medication called LY03020. It is for healthy volunteers and for people with stable schizophrenia. The study aims to see how well the body handles the drug and what side effects might occur.
This trial tests an investigational medication called VV119 for adults experiencing a sudden worsening of schizophrenia symptoms. It aims to see if the drug is safe and effective in reducing symptoms like delusions, hallucinations, and disorganized thinking.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This study tests an experimental medication (NBI-1117570) for adults with schizophrenia who are currently in the hospital because of a sudden worsening of symptoms. The goal is to see if this new treatment can help control symptoms better.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.